



ASIAPHARM Group Ltd

Press Release

ASIAPHARM AWARDS EXCLUSIVE PRC DISTRIBUTION AGREEMENT FOR ITS PROPRIETARY NEUROLOGY DRUG *JINSIPING* TO INTERNATIONAL PHARMACEUTICAL CONGLOMERATE SANDOZ, A NOVARTIS COMPANY.

- **Expansion of *JinSiPing*'s market coverage — will add new growth impetus for Asiapharm**
- **Exclusive distribution agreement underscores AsiaPharm's strategy to enhance the Group's distribution network**
- **Move reaffirms international recognition of AsiaPharm and opens up additional collaborative opportunities for the Group**

Singapore, 13 December 2007 – Singapore Exchange Main Board-listed AsiaPharm Group Ltd. (“AsiaPharm” or “the Group” or “亚洲药业集团有限公司”), a leading specialty pharmaceutical group in the People’s Republic of China (“PRC”) announced today that its wholly owned subsidiary Nanjing Sike Pharmaceutical Co., Ltd. (“Sike” or “南京思科药业有限公司”) has appointed international pharmaceutical conglomerate Sandoz, a Novartis company (“Sandoz”), as the exclusive distribution partner in the PRC for its proprietary Parkinson’s Disease drug *JinSiPing*.

Through this latest agreement, Sandoz will leverage on its sales network to expand *JinSiPing*'s market penetration and product recognition in the PRC over the next five

years – with particular focus on major cities such as Beijing, Shanghai, Nanjing and Guangzhou – through marketing, seminars and other promotional activities. Underlining this collaboration is AsiaPharm’s business strategy to expand market coverage of its proprietary pharmaceutical drugs.

Listed as an approved drug under the PRC National Health Insurance Scheme (“NHI”), *JinSiPing* is one of the leading anti-Parkinson’s disease treatment drugs in the country. Clinically proven to be highly effective in the treatment of Parkinson’s disease and senile dementia by increasing dopamine levels in the patient’s brain, *JinSiPing* is well-received in the PRC, which currently has over 1.7 million afflicted patients.

Commenting on the appointment of Sandoz, Executive Chairman of AsiaPharm, Mr Liu Dianbo (刘殿波), said, “As our products portfolio continues to expand, collaborative opportunities such as this partnership with internationally renowned pharmaceutical company Sandoz will benefit AsiaPharm both financially and strategically. Harnessing such synergistic partnerships, the Group can focus on our core strengths in product development, marketing and explore further business opportunities.

“Collaborative distribution agreements with reputable partners such as Sandoz are a testimony of AsiaPharm’s growing international reputation as a leader within the PRC pharmaceutical industry. In line with the Group’s integration of our acquired subsidiaries, AsiaPharm will explore initiatives to further enhance margins, reduce operating expenses, and increase value for our stakeholders,” commented Mr. Liu.

##END##

About AsiaPharm Group Ltd.

Established in 1994, we are today a leading specialty pharmaceutical group in the People’s Republic of China (“PRC”) focusing on the research and development, production and sale of natural drugs and drug delivery systems. Fully equipped, integrated and GMP-certified, our ultra-modern facilities in Yantai and Nanjing enables us to carry out all aspects of pre-clinical evaluation – from pharmaceutical to pharmacology research, drug safety evaluation and clinical

trials – as well as full production of our natural and new DDS technology drugs. AsiaPharm currently employs approximately 140 researchers and has close collaborative relationships with renowned universities and research institutions around the globe to complement its R&D efforts, enabling AsiaPharm to stay at the forefront of specialty pharmaceutical developments. To reach our customers, we have established an extensive distribution network of 35 sales support offices, covering 30 provinces, municipalities, and autonomous regions, reaching approximately 2500 hospitals. This is further supported by 500 sales and marketing personnel. In line with our international expansion strategy, AsiaPharm has established a market presence in Vietnam, Pakistan and Korea.

Issued on behalf of AsiaPharm Group Ltd. by WeR1 Consultants Pte Ltd

Media Contact Info

WeR1 Consultants Pte Ltd

29 Scotts Road,

Singapore 228224

Tel : (65) 6737 4844

Fax: (65) 6737 4944

Lai Kwok Kim, laikkin@wer1.net or Yim Jeng Yuh, yimjy@wer1.net